{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:54:27Z","timestamp":1790398467133,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research and Development Fund of the Faculty of Medicine Siriraj Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Women with chronic abnormal uterine bleeding-ovulatory dysfunction (AUB-O) are at increased risk of endometrial neoplasia. We conducted a non-inferiority randomized controlled trial to determine the effectiveness of two cyclic-progestin regimens orally administered 10 d\/month for 6\u00a0months on endometrial protection and menstruation normalization in women with AUB-O. There were 104 premenopausal women with AUB-O randomized to desogestrel (DSG 150\u00a0\u00b5g\/d, n\u2009=\u200950) or medroxyprogesterone acetate (MPA 10\u00a0mg\/d, n\u2009=\u200954) group. Both groups were comparable in age (44.8\u2009\u00b1\u20095.7 vs. 42.5\u2009\u00b1\u20097.1\u00a0years), body mass index (24.8\u2009\u00b1\u20094.7 vs. 24.9\u2009\u00b1\u20094.7\u00a0kg\/m<jats:sup>2<\/jats:sup>), and AUB characteristics (100% irregular periods). The primary outcome was endometrial response rate (the proportion of patients having complete pseudodecidualization in endometrial biopsies during treatment cycle-1). The secondary outcome was clinical response rate (the proportion of progestin withdrawal bleeding episodes with acceptable bleeding characteristics during treatment cycle-2 to cycle-6). DSG was not inferior to MPA regarding the endometrial protection (endometrial response rate of 78.0% vs. 70.4%, 95% CI of difference \u2212 9.1\u201324.4%, non-inferiority limit of \u2212 10%), but it was less effective regarding the menstruation normalization (acceptable bleeding rate of 90.0% vs 96.6%, <jats:italic>P<\/jats:italic>\u2009=\u20090.016).<\/jats:p><jats:p><jats:bold>Clinical trial registration<\/jats:bold>: ClinicalTrials.gov (NCT02103764, date of approval 18 Feb 2014).<\/jats:p>","DOI":"10.1038\/s41598-022-05578-0","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T11:18:28Z","timestamp":1643627908000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The effectiveness of desogestrel for endometrial protection in women with abnormal uterine bleeding-ovulatory dysfunction: a non-inferiority randomized controlled trial"],"prefix":"10.1038","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct02103764","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nisarath","family":"Soontrapa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manee","family":"Rattanachaiyanont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malee","family":"Warnnissorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanyarat","family":"Wongwananuruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchada","family":"Indhavivadhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasong","family":"Tanmahasamut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitirat","family":"Techatraisak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surasak","family":"Angsuwathana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"5578_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ijgo.12666","volume":"143","author":"MG Munro","year":"2018","unstructured":"Munro, M. G., Critchley, H. O. D. & Fraser, I. S. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int. J. Gynaecol. Obstet. 143, 393\u2013408 (2018).","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"5578_CR2","first-page":"591","volume-title":"Clinical Gynecologic Endocrinology and Infertility","author":"MA Fritz","year":"2011","unstructured":"Fritz, M. A. Abnormal uterine bleeding. In Clinical Gynecologic Endocrinology and Infertility (eds Fritz, M. A. & Speroff, L.) 591\u2013621 (Lippincott Williams & Wilkins, 2011)."},{"key":"5578_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-5122(03)00068-9","volume":"45","author":"A Ferenczy","year":"2003","unstructured":"Ferenczy, A. Pathophysiology of endometrial bleeding. Maturitas 45, 1\u201314 (2003).","journal-title":"Maturitas"},{"key":"5578_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/S0002-9378(96)70391-5","volume":"174","author":"DV Horbelt","year":"1996","unstructured":"Horbelt, D. V., Roberts, D. K., Parmley, T. H. & Walker, N. J. Ultrastructure of the microvasculature in human endometrial hyperplasia. Am. J. Obstet. Gynecol. 174, 174\u2013183 (1996).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"5578_CR5","first-page":"148","volume":"94","author":"O Abulafia","year":"1999","unstructured":"Abulafia, O. & Sherer, D. M. Angiogenesis of the endometrium. Obstet. Gynecol. 94, 148\u2013153 (1999).","journal-title":"Obstet. Gynecol."},{"key":"5578_CR6","first-page":"CD001895","volume":"9","author":"M Hickey","year":"2012","unstructured":"Hickey, M., Higham, J. M. & Fraser, I. Progestogens with or without oestrogen for irregular uterine bleeding associated with anovulation. Cochrane Database Syst. Rev. 9, CD001895 (2012).","journal-title":"Cochrane Database Syst. Rev."},{"key":"5578_CR7","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/0002-9378(71)90259-6","volume":"110","author":"L Nilsson","year":"1971","unstructured":"Nilsson, L. & Rybo, G. Treatment of menorrhagia. Am. J. Obstet. Gynecol. 110, 713\u2013720 (1971).","journal-title":"Am. J. Obstet. Gynecol."},{"key":"5578_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0039-128X(00)00174-4","volume":"65","author":"R Sitruk-Ware","year":"2000","unstructured":"Sitruk-Ware, R. Progestins and cardiovascular risk markers. Steroids 65, 651\u2013658 (2000).","journal-title":"Steroids"},{"key":"5578_CR9","doi-asserted-by":"publisher","first-page":"104S","DOI":"10.1016\/S0002-9343(99)80067-9","volume":"98","author":"PD Darney","year":"1995","unstructured":"Darney, P. D. The androgenicity of progestins. Am. J. Med. 98, 104S-110S (1995).","journal-title":"Am. J. Med."},{"key":"5578_CR10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.steroids.2003.08.003","volume":"68","author":"FZ Stanczyk","year":"2003","unstructured":"Stanczyk, F. Z. All progestins are not created equal. Steroids 68, 879\u2013890 (2003).","journal-title":"Steroids"},{"issue":"Suppl 1","key":"5578_CR11","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.maturitas.2003.09.014","volume":"46","author":"AE Schindler","year":"2003","unstructured":"Schindler, A. E. et al. Classification and pharmacology of progestins. Maturitas 46(Suppl 1), S7\u2013S16 (2003).","journal-title":"Maturitas"},{"key":"5578_CR12","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1479-828X.1990.tb02028.x","volume":"30","author":"IS Fraser","year":"1990","unstructured":"Fraser, I. S. Treatment of ovulatory and anovulatory dysfunctional uterine bleeding with oral progestogens. Aust. N Z J. Obstet. Gynaecol. 30, 353\u2013356 (1990).","journal-title":"Aust. N Z J. Obstet. Gynaecol."},{"key":"5578_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1097\/00003081-199538040-00017","volume":"38","author":"SC Stone","year":"1995","unstructured":"Stone, S. C. Desogestrel. Clin. Obstet. Gynecol. 38, 821\u2013828 (1995).","journal-title":"Clin. Obstet. Gynecol."},{"key":"5578_CR14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1177\/106002809502907-817","volume":"29","author":"B Kaplan","year":"1995","unstructured":"Kaplan, B. Desogestrel, norgestimate, and gestodene: The newer progestins. Ann. Pharmacother. 29, 736\u2013742 (1995).","journal-title":"Ann. Pharmacother."},{"key":"5578_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.3109\/09513590.2016.1152238","volume":"32","author":"N Trivedi","year":"2016","unstructured":"Trivedi, N., Chauhan, N. & Vaidya, V. Effectiveness and safety of dydrogesterone in regularization of menstrual cycle: A post-marketing study. Gynecol. Endocrinol. 32, 667\u2013671 (2016).","journal-title":"Gynecol. Endocrinol."},{"key":"5578_CR16","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3109\/09513590.2015.1115832","volume":"32","author":"N Podzolkova","year":"2016","unstructured":"Podzolkova, N., Tatarchuk, T., Doshchanova, A., Eshimbetova, G. & Pexman-Fieth, C. Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: A multicenter observational study. Gynecol. Endocrinol. 32, 246\u2013249 (2016).","journal-title":"Gynecol. Endocrinol."},{"key":"5578_CR17","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.12998\/wjcc.v8.i15.3259","volume":"8","author":"L Wang","year":"2020","unstructured":"Wang, L., Guan, H. Y., Xia, H. X., Chen, X. Y. & Zhang, W. Dydrogesterone treatment for menstrual-cycle regularization in abnormal uterine bleeding - ovulation dysfunction patients. World J. Clin. Cases 8, 3259\u20133266 (2020).","journal-title":"World J. Clin. Cases"},{"key":"5578_CR18","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.bpobgyn.2014.10.010","volume":"29","author":"MW Seif","year":"2015","unstructured":"Seif, M. W., Diamond, K. & Nickkho-Amiry, M. Obesity and menstrual disorders. Best Pract. Res. Clin. Obstet. Gynaecol. 29, 516\u2013527 (2015).","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"5578_CR19","unstructured":"National Institute for Health Care and Excellence. Heavy menstrual bleeding, (London, 2007)."},{"key":"5578_CR20","doi-asserted-by":"crossref","unstructured":"Committee on Practice, B.-G. Practice bulletin no. 128: Diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet. Gynecol. 120, 197\u2013206 (2012).","DOI":"10.1097\/AOG.0b013e318262e320"},{"key":"5578_CR21","unstructured":"World Health Organization. Regional Office for the Western Pacific. The Asia-Pacific Perspective: Redefining Obesity and Its Treatment, (Health Communications Australia, 2000)."},{"key":"5578_CR22","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ygyno.2006.03.046","volume":"103","author":"GL Maxwell","year":"2006","unstructured":"Maxwell, G. L. et al. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk. Gynecol. Oncol. 103, 535\u2013540 (2006).","journal-title":"Gynecol. Oncol."},{"key":"5578_CR23","doi-asserted-by":"crossref","unstructured":"Beral, V., Bull, D., Reeves, G. & Million Women Study, C. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365, 1543\u20131551 (2005).","DOI":"10.1016\/S0140-6736(05)66455-0"},{"key":"5578_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1447-0756.2005.00253.x","volume":"31","author":"M Rattanachaiyanont","year":"2005","unstructured":"Rattanachaiyanont, M. et al. Clinical and pathological responses of progestin therapy for non-atypical endometrial hyperplasia: A prospective study. J. Obstet. Gynaecol. Res. 31, 98\u2013106 (2005).","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"5578_CR25","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/01.gme.0000178450.29377.c9","volume":"12","author":"C Di Carlo","year":"2005","unstructured":"Di Carlo, C. et al. Bleeding patterns during continuous estradiol with different sequential progestogens therapy. Menopause 12, 520\u2013525 (2005).","journal-title":"Menopause"},{"key":"5578_CR26","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0015-0282(16)35163-9","volume":"15","author":"M Roland","year":"1964","unstructured":"Roland, M., Clyman, M. J., Decker, A. & Ober, W. B. Classification of endometrial response to synthetic progestogen-estrogen compounds. Fertil. Steril. 15, 143\u2013163 (1964).","journal-title":"Fertil. Steril."},{"key":"5578_CR27","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12944-017-0612-5","volume":"16","author":"Y Jiang","year":"2017","unstructured":"Jiang, Y. & Tian, W. The effects of progesterones on blood lipids in hormone replacement therapy. Lipids Health Dis. 16, 219 (2017).","journal-title":"Lipids Health Dis."},{"key":"5578_CR28","doi-asserted-by":"crossref","unstructured":"Committee on Practice, B.-G. Practice bulletin no. 136: Management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet. Gynecol. 122, 176\u2013185 (2013).","DOI":"10.1097\/01.AOG.0000431815.52679.bb"},{"key":"5578_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2288-4-26","volume":"4","author":"M Saghaei","year":"2004","unstructured":"Saghaei, M. Random allocation software for parallel group randomized trials. BMC Med. Res. Methodol. 4, 26 (2004).","journal-title":"BMC Med. Res. Methodol."},{"key":"5578_CR30","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1177\/1933719113477492","volume":"20","author":"IS Fraser","year":"2013","unstructured":"Fraser, I. S. et al. Improving the objective quality of large-scale clinical trials for women with heavy menstrual bleeding: Experience from 2 multi-center, randomized trials. Reprod. Sci. 20, 745\u2013754 (2013).","journal-title":"Reprod. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05578-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05578-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05578-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T22:29:53Z","timestamp":1669328993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-05578-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5578"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-05578-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"29 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1662"}}